HLS Therapeutics Valuation
| HLS Stock | CAD 3.52 0.04 1.12% |
At this time, the firm appears to be overvalued. HLS Therapeutics retains a regular Real Value of C$2.97 per share. The prevalent price of the firm is C$3.52. Our model calculates the value of HLS Therapeutics from analyzing the firm fundamentals such as return on equity of -0.24, and Return On Asset of -0.0274 as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting HLS Therapeutics' valuation include:
Price Book 1.0181 | Enterprise Value 184.8 M | Enterprise Value Ebitda 7.8679 | Price Sales 1.9654 | Forward PE 185.1852 |
Overvalued
Today
Please note that HLS Therapeutics' price fluctuation is unstable at this time. Calculation of the real value of HLS Therapeutics is based on 3 months time horizon. Increasing HLS Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since HLS Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of HLS Stock. However, HLS Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 3.52 | Real 2.97 | Hype 3.52 | Naive 3.56 |
The intrinsic value of HLS Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence HLS Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of HLS Therapeutics helps investors to forecast how HLS stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of HLS Therapeutics more accurately as focusing exclusively on HLS Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use HLS Therapeutics' intrinsic value based on its ongoing forecasts of HLS Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against HLS Therapeutics' closest peers.
HLS Therapeutics Cash |
|
HLS Valuation Trend
Knowing HLS Therapeutics' actual value is paramount for traders when making sound investment determinations. Using both HLS Therapeutics' enterprise value as well as its market capitalization is the best way to estimate the value of the company and is usually enough for investors to make market timing decisions.
HLS Therapeutics Total Value Analysis
HLS Therapeutics is currently projected to have takeover price of 184.77 M with market capitalization of 111.91 M, debt of 87.62 M, and cash on hands of 20.72 M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the HLS Therapeutics fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
184.77 M | 111.91 M | 87.62 M | 20.72 M |
HLS Therapeutics Investor Information
About 65.0% of the company shares are owned by institutional investors. The company has price-to-book (P/B) ratio of 1.02. Some equities with similar Price to Book (P/B) outperform the market in the long run. HLS Therapeutics recorded a loss per share of 0.97. The entity last dividend was issued on the 27th of April 2023. The firm had 1:5 split on the 26th of October 2006. Based on the key indicators related to HLS Therapeutics' liquidity, profitability, solvency, and operating efficiencyBased on the analysis of, HLS Therapeutics is not in a good financial situation at this time. It has a very high probability of going through financial hardship in January.HLS Therapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. HLS Therapeutics has an asset utilization ratio of 30.17 percent. This suggests that the Company is making C$0.3 for each dollar of assets. An increasing asset utilization means that HLS Therapeutics is more efficient with each dollar of assets it utilizes for everyday operations.HLS Therapeutics Ownership Allocation
HLS Therapeutics has a total of 31.79 Million outstanding shares. Over half of HLS Therapeutics' outstanding shares are owned by outside corporations. These outside corporations are typically referred to as corporate investors that purchase positions in a given instrument to benefit from reduced trade commissions. Therefore, these institutions are subject to different rules and regulations than regular investors in HLS Therapeutics. Please watch out for any change in the institutional holdings of HLS Therapeutics as this could mean something significant has changed or is about to change at the company. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.HLS Therapeutics Profitability Analysis
The company reported the revenue of 63.07 M. Net Loss for the year was (27.53 M) with profit before overhead, payroll, taxes, and interest of 50.76 M.HLS Therapeutics Past Distributions to stockholders
About HLS Therapeutics Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of HLS Therapeutics. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of HLS Therapeutics based exclusively on its fundamental and basic technical indicators. By analyzing HLS Therapeutics's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of HLS Therapeutics's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of HLS Therapeutics. We calculate exposure to HLS Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of HLS Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 55.5 M | 58.2 M | |
| Pretax Profit Margin | (0.44) | (0.42) | |
| Operating Profit Margin | (0.16) | (0.16) | |
| Net Loss | (0.44) | (0.41) | |
| Gross Profit Margin | 0.88 | 0.92 |
Other Information on Investing in HLS Stock
HLS Therapeutics financial ratios help investors to determine whether HLS Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in HLS with respect to the benefits of owning HLS Therapeutics security.